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Change in the NT-proBNP/Mature BNP Molar Ratio Precedes
Worsening Renal Function in Patients With Acute Heart Failure:
A Novel Predictor Candidate for Cardiorenal Syndrome
Hiroyuki Takahama, MD, PhD; Toshio Nishikimi, MD, PhD; Seiji Takashio, MD, PhD; Tomohiro Hayashi, MD, PhD;
Chiaki Nagai-Okatani, PhD; Takashi Asada, MT; Akihiro Fujiwara, MT; Yasuaki Nakagawa, MD, PhD; Masashi Amano, MD;
Yasuhiro Hamatani, MD; Atsushi Okada, MD; Makoto Amaki, MD, PhD; Takuya Hasegawa, MD, PhD; Hideaki Kanzaki, MD, PhD;
Kunihiro Nishimura, MD, PhD; Satoshi Yasuda, MD, PhD; Kenji Kangawa, PhD; Toshihisa Anzai, MD, PhD;* Naoto Minamino, PhD;*
Chisato Izumi, MD, PhD*
Background-—Early detection for worsening renal function (WRF) is indispensable in patients with acute decompensated heart
failure (HF). We tested the hypothesis that the difference in the circulating levels of each B-type or brain natriuretic peptide (BNP)
molecular form is associated with the occurrence of WRF.
Methods and Results-—Circulating levels of proBNP, the NT-proBNP (N-terminal proBNP), and total BNP (proBNP+mature BNP)
were prospectively measured in patients with acute decompensated HF using specific and sensitive enzyme immunochemilu-
minescent assays. An estimated mature BNP (emBNP) concentration was calculated by subtracting proBNP levels from total BNP
levels. WRF was defined as a >20% decrease in the estimated glomerular filtration rate during the hospitalization. One-way
repeated-measures ANOVA was used to compare the changes of variables between the patients with and without WRF. In patients
with acute decompensated HF (New York Heart Association class III–IV; 96%) hospitalized for HF, NT-proBNP levels did not differ
during the hospitalization between patients with and without WRF (n=42 and 140, respectively). By contrast, emBNP levels were
lower in patients with WRF than in those without WRF on day 3 after admission. NT-proBNP/emBNP molar ratios were elevated on
day 3 after admission in the patients with WRF, before estimated glomerular filtration rate declined, but were unchanged in patients
without WRF. On day 3 after hospital admission, NT-proBNP/emBNP ratios were strongly associated with percentage decreases in
estimated glomerular filtration rate.
Conclusions-—These findings suggest that elevation of NT-proBNP/emBNP ratio precedes WRF in patients with acute HF and can
be a potentially useful biomarker for risk stratification of cardiorenal syndrome. ( J Am Heart Assoc. 2019;8:e011468. DOI: 10.
1161/JAHA.118.011468.)
Key Words: acute heart failure • BNP (B-type or brain natriuretic peptide) • cardiorenal syndrome • renal function
R enal impairment is recognized to be an independent riskfactor for morbidity and mortality in patients with heart
failure (HF).1,2 As a result of the diverse mechanisms
underlying the pathophysiological features of HF, renal and
cardiac functions have close and complementary inter-
connections; and worsening renal function (WRF) often
complicates patients with HF. This is termed “cardiorenal
syndrome.” Particularly in patients with acute decompensated
HF (ADHF), risk factors for WRF, such as hemodynamic
disorder and neurohormonal activation, underlie vulnerable
phases after the acute onset of HF.3–6 There is, thus, an
unmet need for a biomarker for early detection of WRF,
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evaluation of HF severity, and prediction of clinical outcomes
in patients with ADHF.
The B-type or brain natriuretic peptide (BNP) gene encodes
a 134–amino acid pre-proBNP precursor, which is converted
to the 108–amino acid proBNP (proBNP) through cleavage of
a 26–amino acid signal peptide in endoplasmic reticulum.7
Further processing of proBNP leads to the production of 2
molecular forms: biologically active mature BNP and inactive
NT-proBNP (N-terminal proBNP) in trans-Golgi network.8 In
addition, substantial amounts of proBNP are secreted into the
blood without processing and can be detected in the plasma
of both healthy subjects and patients with HF.9,10 The
conventional BNP assay kit using sandwich immunoassay
usually cross-reacts with proBNP. Consequently, the BNP level
measured using a conventional BNP assay is the total BNP
measured as the sum of the mature BNP and proBNP
(Figure 1).
We recently developed 2 chemiluminescent enzyme
immunoassays (CLEIAs) for proBNP and total BNP; in the
latter assay, proBNP and mature BNP are equally recognized
on a molar basis. Using these assay systems, we can
accurately measure the ratio of proBNP/total BNP and
calculate the estimated mature BNP (emBNP) level by
subtracting proBNP from total BNP.11 In addition, using this
system, we recently reported that the ratio of proBNP/total
BNP is increased in patients with severe HF.12 More
important, definite differences exist in the clearance and
excretion rates of mature BNP and NT-proBNP: mature BNP is
cleared via membrane-bound natriuretic peptide receptors A
and C (NPR-A and NPR-C, respectively), neprilysin, and an
unknown protease, among others, whereas NT-proBNP is
mainly cleared through renal excretion.13,14 The regulation of
NPR-A and NPR-C expression in patients with HF compro-
mised by WRF remains controversial. Some earlier clinical and
experimental studies suggest NPRs are up-regulated in
patients with HF,15 hypertensive animal models,16 and a
renal ischemic reperfusion animal model,17 suggesting that
mature BNP plays a role in renal disease via NPR-A/cGMP
cascade.15 Furthermore, others and we have shown that
mature BNP/total BNP ratio is increased in acute HF.18,19 We
hypothesized that the difference in the circulating levels of
mature BNP and NT-proBNP varies with the pathological
condition such that their ratio is associated with the
occurrence of WRF and future clinical outcome.
Methods
Data, Materials, and Code Disclosure Statement
The data that support the findings of this study are available
from the corresponding author (H.T.) on reasonable request.
Study Design
This was a prospective cross-sectional study of changes in the
plasma levels of several types of BNP in patients with ADHF
admitted to the National Cerebral and Cardiovascular Center
of Japan.
Study Population
Eligibility requirements were as follows: (1) age from 20 to
85 years, (2) hospitalization to our hospital because of ADHF,
(3) enrollment within 48 hours after admission for ADHF, and
(4) provided written informed consent. Patients on dialysis
were excluded, as were patients with acute coronary
syndrome. Ultimately, we analyzed 182 patients (aged 26–
85 years) enrolled between June 2012 and October 2015.
Blood samples for measurement of plasma NT-proBNP and
total BNP levels were collected within 48 hours of admission,
3 days after admission, 7 days after admission, and before
discharge. The “before discharge” blood sampling was done a




• Little has been known about the changes in the circulating
levels of each B-type or brain natriuretic peptide (BNP)
molecular form in patients with acute heart failure (HF) and
worsening renal function (WRF).
• This study found that in patients with acute decompensated
HF, NT-proBNP (N-terminal proBNP) levels did not differ
during the hospitalization between patients with and without
WRF; by contrast, estimated mature BNP levels were lower
in patients with WRF than in those without WRF on day 3
after admission.
• NT-proBNP/estimated mature BNP ratio, but not NT-proBNP
alone, was strongly associated with changes of renal
function during hospitalization.
What Are the Clinical Implications?
• Renal impairment is a strong prognostic indicator for acute
HF, and early detection for WRF is indispensable.
• WRF is often asymptomatic, and is detected only through
increases in serum creatinine levels.
• This study shows that elevation of NT-proBNP/estimated
mature BNP ratio precedes WRF in patients with acute HF;
therefore, we propose that the NT-proBNP/estimated
mature BNP ratio could be a novel biomarker for early
detection of WRF in patients during the acute phase after
the onset of acute HF.
DOI: 10.1161/JAHA.118.011468 Journal of the American Heart Association 2
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Biomarker Testing
Blood samples were collected into polyethylene-telephthalate
tubes containing EDTA-2Na (1.5 mg/mL) and aprotinin (500
kallikrein inhibitor units/mL) (Neotube NP-EA0305; Nipro,
Osaka, Japan). The collected blood samples were mixed well,
stored at 4°C, and centrifuged within 6 hours. The resulting
plasma samples were immediately frozen and stored at
80°C until measurements were made. The research group
at Shionogi Corp, our collaborator in the development of the
total BNP and proBNP assays, previously confirmed that use
of polyethylene-telephthalate tubes and addition of aprotinin
at the time of blood collection greatly increase the stability
of BNP immunoreactivity measured with an antibody pair
that is identical to the pair used in the present total BNP
assay. In these experiments, >90% of BNP immunoreactivity
was always recovered under the blood collection and storage
conditions used in the present study (H. Shimizu, PhD, K.
Masuta, BS, Shionogi Corp, personal communications, 2012).
Although several proteases, including neprilysin, dipeptidyl
peptidase-4, and insulin-degrading enzyme, are known to
quickly degrade mature BNP-32, BNP immunoreactivity
detected with the aforementioned antibody pair is believed
to be quantitatively recovered and measured with this
method and CLEIA system. Plasma total BNP and proBNP
were measured using our recently developed CLEIAs, as
previously described.19,20 Briefly, in both CLEIAs, an antibody
recognizing a common epitope in the C-terminal region of
proBNP and mature BNP was used as a capture antibody. An
antibody recognizing the N-terminal region of proBNP and one
recognizing the ring region of BNP were used as detection
antibodies in the proBNP and total BNP CLEIAs, respectively.
More important, because the affinities of the 2 detection
antibodies for their respective epitopes were nearly the same,
and a common capture antibody was used, we were able to
accurately measure the proBNP and total BNP and then
estimate the mature BNP levels, as described previously.11,19
The total BNP levels in this study correspond to those
measured using the conventional BNP assays, which were
measured as the sum of the mature BNP and proBNP and on an
equimolar basis in this study. Thus, emBNP was calculated as
follows: emBNP=total BNP (sum of proBNP and mature BNP)
proBNP, as shown in Figure 1. Glycosylated proBNP, with a
relative molecular mass of 32 kDa (HyTest Ltd, Turku, Finland),
served as the standard. Intra-assay (8 replicates) and interas-
say (10 replicates) coefficients of variation of the standard
peptide at 2.6, 8.9, and 76.7 pmol/L were in the ranges of 1.5%
to 5.4% and 4.1% to 5.5%, respectively, in the proBNP assay. NT-
proBNP concentrations were measured using the Elecsys
proBNP II assay (Roche Diagnostics, Basel, Switzerland). cGMP
(cyclic guanosine monophosphate), a second messenger for
BNP, was measured with a radioimmunoassay assay kit
(Yamasa Shoyu, Tokyo, Japan). Estimated glomerular filtration
rate (eGFR) was calculated using the equation for Japanese
individuals: 1949serum creatinine1.0949age0.287 (90.739


















Figure 1. Schematic representation of NT-proBNP (N-terminal pro-B-type or brain natriuretic peptide)
assay, (total) BNP assay, and proBNP-specific assay. A, The schema of proBNP processing and secretion
from cardiomyocytes into circulation. Gray/black and green/red bidentate bars indicate the antibodies
specific for the corresponding region of NT-proBNP and mature BNP/proBNP ratio, respectively. Total BNP
indicates sum of mature BNP and proBNP. B, Blue/red bidentate bars indicate the antibodies specific for
the corresponding region of proBNP. Thus, estimated mature BNP (emBNP) was calculated as follows:
emBNP=total BNPproBNP (pmol/L). AAR indicates amino acid residue.
DOI: 10.1161/JAHA.118.011468 Journal of the American Heart Association 3
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Echocardiography
Using medical records, we retrospectively reviewed the
echocardiographic data recorded from the enrolled patients
on admission. Left ventricular (LV) dimensions were measured
according to American Society of Echocardiography guide-
lines. LV ejection fraction was measured using the Simpson
biplane method or the semiquantitative 2-dimensional visual
estimate method, as previously described.22
Diagnosis of HF
ADHF was diagnosed using the Framingham criteria.23 The
final diagnosis of cardiomyopathy was based on the definition
from the World Health Organization/International Society and
Federation of Cardiology Task Force.24 All patients with
ischemic heart disease were diagnosed using coronary
angiography or coronary computed tomography.
Definition of WRF
We compared the eGFRs measured at 2 time points, on
admission and before discharge. In accordance with the
previous studies,25,26 WRF was defined as a >20% decrease in
eGFR before discharge compared with levels on admission in
this study.
Clinical Outcomes
After the admission date, we investigated all causes of death,
implantation of a LV assist device, and rehospitalization for HF
for the 2 years through medical chart review or a letter.
Composite clinical events were defined as occurrences of the
following events, at least as follows: all causes of death,
implantation of an LV assist device, and rehospitalization for
HF.
Ethics
Written informed consent was obtained from all subjects. This
study was approved by our institutional ethics committee
(M23-090) and was conducted in accordance with the
Declaration of Helsinki.
Statistical Analysis
Data are expressed as medians and interquartile ranges.
Categorical variables were expressed as patient number (N)
and percentage. Fisher’s exact test or v2 statistic was used to
compare categorical variables, as appropriate. For baseline
patient characteristics, Wilcoxon’s rank sum test was used for
comparison of continuous variables between 2 groups
(Figure 2, Tables 1 through 3). One-way repeated-measures
ANOVA was used to compare the changes of eGFR, each BNP
level (Figure 3), NT-proBNP/emBNP ratio (Figure 4A), and
cGMP (Figure 4B) over time (1=admission, 2=3 days after
admission, 3=7 days after admission, and 4=before dis-
charge) between the patients with WRF and without WRF.
Linear regression models were performed to test the differ-
ence in the relationship between dependent variables (per-
centage decreases in eGFR) and independent variables (NT-
proBNP/emBNP ratio) in Tables 4 through 6. Linear regres-
sion was also used to assess the relationships between eGFR
A B
Figure 2. Differences in clinical backgrounds in patients with and without worsening renal function
(WRF). A, Change (D) in systolic blood pressure in the patients with WRF and without WRF: Dsystolic blood
pressure=systolic blood pressure on admissionsystolic blood pressure before discharge. Larger
decreases in systolic blood pressure were found in the patients with WRF (red) compared with those
without WRF (blue); *P<0.05 vs the patients without WRF. B, DBody weight in the patients with WRF and
without WRF: Dbody weight=body weight on admissionbody weight before discharge. Body weight tended
to be larger in the patients with WRF (red) compared with those without WRF (blue); P=0.07 vs the patients
without WRF. BP, blood pressure.
DOI: 10.1161/JAHA.118.011468 Journal of the American Heart Association 4
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and each BNP level (Figure 5A through 5C). We also evaluated
the group differences in the relationship (eGFR and NT-
proBNP/emBNP ratio) from below and above median NT-
proBNP level by the interaction term between NT-proBNP
(below or above median value) and NT-proBNP/emBNP ratios
(Figure 5D). Univariate survival analyses were performed with
the Cox proportional hazards model (Table 7). Hazard ratios
with 95% confidential intervals (CI)s and probability (P) values,
determined using the likelihood ratio test, are presented. The
area under receiver operating characteristic curve and C-
statistics were also calculated. Areas under receiver operating
characteristic curves are compared using an algorithm
developed by DeLong et al.27 The pairwise comparisons of
area under multiple receiver operating characteristic curves
were conducted by using roccomp command in STATA.
Multivariable analysis/regression was used to test multiple
covariates. All tests were 2 tailed, and P<0.05 was considered
significant. All statistical analyses were performed using JMP
9 statistical analysis software (SAS Institute Japan, Inc, Tokyo,
Japan) and Stata 15 (Stata Corporation LLC, College Station,
TX).
Results
Characteristics of Patients With WRF
Occurrences During Hospitalization
Among the 182 enrolled patients, WRF occurred in 42 during
their hospitalization (median length of hospital stay, 22 days;
interquartile range, 14–35 days), and the follow-up term
(from the baseline blood collection date to the blood
collection before discharge) was a median of 18 days
(interquartile range, 13–29 days). Table 1 summarizes the
characteristics of patients with and without occurrences of
WRF during hospitalization for ADHF. The patients with WRF
tended to be older and were more likely to be women. There
were no statistical differences in the cause of HF, comor-
bidities, or echocardiographic findings between those who
experienced WRF and those who did not. Systolic blood
pressure and eGFR were higher and hemoglobin and total
BNP tended to be lower in the patients with WRF than in
those without it. As shown in Figure 2, in the patients who
experienced WRF during hospitalization, the change in
systolic blood pressure between admission to the hospital
and discharge (D systolic blood pressure) was larger in
patients with WRF than in those without WRF. As shown in
Table 2, total dosages of furosemide by intravenous admin-
istration for the first 3 days were higher in the patients with
WRF than in those without WRF (P<0.05). Dosages of other
diuretic agents did not differ between the 2 groups. A
frequency of carperitide administration did not differ between
the 2 groups. Decreases in body weight during hospitalization
Table 1. Baseline Characteristics of Patients With and
Without Occurrences of WRF
Characteristics WRF () WRF (+)
Patients, N 140 42
Age, y 73 (66–80) 78 (72–81)
Female sex, N (%) 43 (31) 20 (48)
BMI, kg/m2 23.0 (20.5–23.3) 23.5 (22.0–27.2)
NYHA class III
or IV, N (%)
133 (95) 40 (95)
Cause, N (%)
Ischemic 44 (31) 13 (31)
Nonischemic 32 (23) 8 (19)
Valvular 31 (22) 10 (24)
Hypertensive 26 (19) 6 (14)
Others 7 (5) 5 (12)
History, N (%)
HF hospitalization 60 (43) 21 (50)
Hypertension 95 (68) 30 (73)
DM 61 (44) 15 (35)
Dyslipidemia 72 (51) 21 (50)
Vital signs on admission
Systolic blood
pressure, mm Hg
133 (112–154) 147 (123–169)*
Heart rate, bpm 85 (70–104) 95 (78–115)
Echocardiography
LVDd, mm 56 (48–64) 52 (45–59)
LVDs, mm 47 (35–56) 39 (31–53)




42 (32–55) 56 (36–75)*
BUN, mg/dL 24 (19–33) 18 (14–27)
Hemoglobin, g/dL 12.5 (10.7–13.6) 11.1 (9.9–12.9)*
CRP, mg/dL 0.41 (0.14–1.31) 0.48 (0.09–1.59)
Total BNP, pmol/L 116.5 (59.6–192.4) 92.6 (30.0–163.5)
emBNP, pmol/L 43.1 (22.8–73.1) 32.7 (13.0–61.8)
NT-proBNP, pmol/L 522.8 (263.4–1103.5) 493.2 (148.6–982.0)
Medications, N (%)
ACEi or ARB 86 (61) 26 (62)
b Blockers 99 (71) 22 (52)
Loop diuretics 53 (38) 16 (38)
Values are the median (interquartile range), unless otherwise specified. ACEi indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body
mass index; BNP, B-type or brain natriuretic peptide; bpm, beats per minute; BUN, blood
urea nitrogen; CRP, C-reactive protein; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; emBNP, estimated mature BNP; HF, heart failure; LVDd, left
ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LVEF, left
ventricular ejection fraction; NT-proBNP, N-terminal proBNP; NYHA, New York Heart
Association; WRF, worsening renal function.
*P<0.05 vs WRF ().
DOI: 10.1161/JAHA.118.011468 Journal of the American Heart Association 5
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also tended to be larger in the patients with WRF than in
those without it (P=0.053).
Time Course Changes in NT-proBNP, Total BNP,
and emBNP in Patients With and Without WRF
Figure 3 presented time course changes in eGFR (Figure 3A),
NT-proBNP (Figure 3B), total BNP (Figure 3C), and emBNP
(Figure 3D) in the patients with and without WRF. Before day
3, only 5 WRF events (11% of overall patients with WRD) had
occurred. Patients received blood collection for natriuretic
peptides at day 3 (n=164), at day 7 (n=159), and before
discharge (n=144); and we exclude from the analysis for time
course changes those who did not received all 3 blood
collections. Significant differences between the patients with
and without WRF were found at each time point after day 3 in
total BNP and mature BNP, but not in NT-proBNP. For time
course changes, NT-proBNP levels did not differ in the
patients with WRF and those without WRF (Figure 3B). In
contrast, both total BNP and emBNP were lower in the
patients with WRF compared with those without WRF after
day 3 (Figure 3C and 3D, respectively).
Figure 4A shows the time courses of the changes in NT-
proBNP/emBNP ratios during hospitalization in the patients
with and without WRF. NT-proBNP/emBNP ratios were
elevated on day 3 after admission in the WRF group but
were unchanged throughout the hospitalization in those
without WRF (Figure 4A). Figure 4B shows the time course
of changes in plasma cGMP in patients with above- and below-
median NT-proBNP/emBNP ratios. Although 1-way repeated
ANOVA revealed no overall differences throughout the
protocol, on day 3 after admission, plasma cGMP levels were
higher in patients with above-median NT-proBNP/emBNP
ratios than in those with below-median NT-proBNP/emBNP
ratios (P<0.05). As the basic characteristics, patients with
above-median NT-proBNP/emBNP ratios were significantly
older and more likely to be women than those with below-
median NT-proBNP/emBNP ratios (Table 3). Higher frequency
of HF hospitalization history was observed in patients with
above-median NT-proBNP/emBNP ratios than those with
below-median NT-proBNP/emBNP ratios. Lower eGFR
(P<0.05), higher blood urea nitrogen (P<0.05), and smaller
LV size (P=0.086) were observed in those with above-median
NT-proBNP/emBNP ratios compared with those with below-
median NT-proBNP/emBNP ratios. LV ejection fraction values
were comparable between the 2 groups. Plasma total BNP
levels also did not differ between them. As the diuretics,
furosemide dosages (intravenous administration) did not differ
between below- and above-median NT-proBNP/emBNP ratio
groups (median value for both, 20 mg; P=0.138). In addition,
there were no statistical differences in use of nitrate
(intravenous administration) or phosphodiesterase type 5
inhibitor between the patients with below- and above-median
NT-proBNP/emBNP ratio. NT-proBNP levels, but not emBNP,
were well associated with eGFR (Figure 5A and 5B). Log [NT-
proBNP/emBNP] was well correlated with log eGFR on
hospital admission (Figure 5C). Moreover, in patients with
above-median NT-proBNP levels on admission, the correlation
was stronger than in those with below-median NT-proBNP
levels (Figure 5D; group difference, P=0.010).
The data summarized in Tables 4 through 6 show the
association of emBNP, NT-proBNP levels, and NT-proBNP/
emBNP ratios on day 3 after hospital admission with
percentage decreases in eGFR during hospitalization. The
emBNP levels on day 3 themselves were not associated with
percentage decreases in eGFR (P=0.696; Table 4). The NT-
proBNP levels on day 3 were moderately associated with
percentage decreases in eGFR (Table 5). The NT-proBNP/
emBNP ratio was strongly associated with percentage
decreases in eGFR, even after adjustments for age, sex, and
other confounding factors (Table 6, models 2–5). Moreover,
the ratio persisted even after adjustments for serum CRP (C-
reactive protein) values (parameter estimate, 1.58;
P<0.0001). In addition, we analyzed predictability of these
parameters for WRF occurrences. The association of both
eGFR and NT-proBNP/emBNP ratio (day 3) with the clinical
events (WRF) was not statistically significant (both receiver
operating characteristic curves and C-statistics, P>0.05).
Predictive Value of NT-proBNP/emBNP Ratios for
Future Adverse Clinical Outcomes in Patients
With ADHF
During the follow-up period (median, 472 days; interquartile
range, 200–712 days), composite clinical events occurred in
70 patients (16 events in patients with WRF, 54 events in
patients without WRF). Table 7 shows the predictive values of
Table 2. Total Dosage of Diuretic Agents in Patients With
WRF and Without WRF for First 3 Days After Admission
Diuretic Agents WRF () WRF (+)
Furosemide (intravenous), mg* 20 (1060) 40 (200)†
Furosemide (oral), mg 10 (240) 30 (280)
Torsemide, mg 0 (28) 0 (16)
Azosemide, mg 0 (180) 0 (180)
Trichlormethiazide, mg 0 (4) 0 (4)
Spironolactone, mg 0 (125) 0 (125)
Tolvaptan, mg 0 (45) 0 (30)
Values are expressed as median (maximum dose). Except furosemide (intravenous), all
other agents were taken by oral administration. WRF indicates worsening renal function.
*The dose is expressed as a total dosage of intravenous furosemide administration for
the first 3 days after hospital admission.
†P<0.05 vs WRF ().
DOI: 10.1161/JAHA.118.011468 Journal of the American Heart Association 6
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BNPs and the NT-proBNP/emBNP ratio in the enrolled
patients with and without WRF. The upper rows of Table 7
show the predictive value of NT-proBNP alone and
NT-proBNP/emBNP ratios measured on admission. In the
patients without WRF, NT-proBNP was associated with clinical
outcomes, but NT-proBNP alone was not associated with
clinical outcomes in patients with WRF. Conversely, NT-
proBNP/emBNP ratios were associated with clinical out-
comes in patients with WRF, but not in those without WRF.
The lower rows of Table 7 show the predictive value of NT-
proBNP alone and NT-proBNP/emBNP ratios measured before
discharge. At that time, NT-proBNP levels were strongly
associated with clinical outcomes in the patients without WRF
but were not associated with clinical outcome in those with
WRF. NT-proBNP/emBNP ratios at discharge had a borderline
association with clinical outcomes in those with WRF.
Discussion
The present study revealed significant differences in the time
course of changes in total BNP and emBNP, but not NT-
proBNP, between patients with and without WRF (Figure 3).
As shown in Table 4, the association of emBNP itself with
percentage decreases in eGFR was weak. In contrast, the
ratio of NT-proBNP/emBNP was strongly associated with
percentage decreases in eGFR. Thus, we propose that
combination of NT-proBNP/emBNP is useful for prediction
of WRF, to account for baseline NT-proBNP levels, which is
influenced by renal clearance. Indeed, the NT-proBNP/emBNP
ratio is strongly associated with renal function in patients with
ADHF (Figure 5). In particular, the ratio was elevated on day 3
after hospital admission in patients with WRF, although eGFR
was not lower in patients with WRF than in those without WRF
during the first 7 days after admission (Figures 3A and 4A).
These findings suggest that elevation of NT-proBNP/emBNP
ratio precedes WRF in patients with acute HF.
Early Detection for WRF in Patients With
Cardiorenal Syndrome
WRF is often asymptomatic and is detected only through
increases in serum creatinine levels. There is, thus, an unmet
need for early detection of WRF during the short-term phase
of decompensated HF. Novel biomarkers for detecting WRF
linked to HF severity are desired, but several confounding
factors (eg, volume state) influence biomarker levels. Indeed,
tubulospecific biomarkers, such as kidney injury molecule 1,
neutrophil gelatinase-associated lipocalin, and N-acetyl-b-D-
glucosaminidase, are useful for early detection of renal
tubular dysfunction in HF; however, their levels are signifi-
cantly affected by diuretic therapy.28 Therefore, biomarkers
for detection of both HF severity and renal function are









Patients, N 91 91
Age, y 73 (63–78) 77 (70–81)*
Female sex, N (%) 24 (26) 37 (41)*
BMI, kg/m2 23.1 (20.4–26.3) 23.1 (21.1–25.5)
NYHA class III or IV, N (%) 87 (95) 87 (96)
Cause, N (%)
Ischemic 29 (32) 28 (31)
Nonischemic
cardiomyopathy
20 (22) 21 (23)
Valvular 18 (20) 23 (25)
Hypertensive 17 (18) 15 (16)
Others 8 (9) 4 (4)
History, N (%)
HF hospitalization 32 (35) 50 (55)*
Hypertension 66 (73) 59 (66)
DM 33 (36) 43 (47)
Dyslipidemia 43 (48) 51 (57)
Vital signs on admission
Systolic blood
pressure, mm Hg
133 (113–152) 137 (110–161)
Heart rate, bpm 88 (71–106) 86 (70–106)
Echocardiography
LVDd, mm 58 (49–64) 53 (46–63)
LVDs, mm 48 (37–58) 41 (32–54)




55 (43–68) 36 (24–48)*
BUN, mg/dL 20 (16–26) 29 (20–42)*
CRP, mg/dL 0.30 (0.11–0.65) 0.68 (0.18–2.58)*
Total plasma BNP,
pmol/L





cGMP, nmol/L 14.0 (8.0–17.0) 13.2 (8.1–19.3)
Medications, N (%)
ACEi or ARB 57 (63) 56 (62)
b Blockers 66 (66) 62 (69)
Loop diuretics 58 (64) 61 (69)
Values are the median (interquartile range), unless otherwise specified. ACEi indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI,
body mass index; BNP, B-type or brain natriuretic peptide; bpm, beats per minute;
BUN, blood urea nitrogen; CRP, C-reactive protein; DM, diabetes mellitus; eGFR,
estimated glomerular filtration rate; emBNP, estimated mature BNP; HF, heart failure;
LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic
diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal proBNP;
NYHA, New York Heart Association.
*P<0.05 vs the patients with below-median NT-proBNP/emBNP ratio.
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clinically required for prediction of cardiorenal syndrome in
patients with HF. Generally, elevation of serum creatinine
levels takes several days after acute renal impairment, which
means a significant time lag for detection of WRF. By contrast,
expression of BNP mRNA is rapidly induced; and peptide
levels of BNP are elevated within 1 hour after myocardial
stretch.29 We, therefore, propose that the NT-proBNP/emBNP

























AD Day 3 Day 7 BD
D WRF (+)
WRF (-)
AD Day 3 Day 7 BD
Figure 3. Time course changes in estimated glomerular filtration rate (eGFR) and each B-type or brain
natriuretic peptide (BNP) molecular form during hospitalization of patients with acute decompensated heart
failure (ADHF). Time course showing eGFR (A), log NT-proBNP (N-terminal pro-BNP; B), log total BNP (C),
and log estimated mature BNP (D) values on hospital admission, 3 days (day 3) and 7 days (day 7) after
admission, and before discharge (BD) in patients with ADHF and with worsening renal function (WRF) (red)
and without WRF (blue). *P<0.05 vs the patients without WRF at the corresponding times, #P<0.05 vs the
overall time course in those without WRF (1-way repeated ANOVA). AD; admission.
A WRF (+)
WRF (-)




AD Day 3 Day 7 BD
Figure 4. Time course changes in NT-proBNP (N-terminal pro-B-type or brain natriuretic peptide)/estimated
mature BNP (emBNP) ratio and cGMP during hospitalization of patients with acute decompensated heart
failure (ADHF). A, Time course of NT-proBNP/emBNP ratios in patients with ADHF and with (red) and without
(blue) worsening renal function (WRF). *P<0.05 vs the patients without WRF at the corresponding times,
#P<0.05 vs the overall time course in those without WRF (1-way repeated ANOVA). B, Time course changes in
plasma cGMP in patients with above-median NT-proBNP/emBNP ratio (red) and with below-median
NT-proBNP/emBNP ratio (blue). One-way repeated ANOVA through protocol: no statistical significance. BD
indicates before discharge. *P<0.05 vs the patients without WRF at each time point. AD; admission.
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patients during the short-term phase after the onset of acute
HF. Consistent with this idea, we demonstrated herein that
NT-proBNP/emBNP ratios were elevated on day 3 after
hospital admission in the patients with WRF (Figure 4A),
before declines in eGFR. These findings support our hypoth-
esis that NT-proBNP/emBNP ratio is potentially useful for
early detection of WRF in patients with acute HF much more
sensitively than changes in eGFR. The patients with WRF were
mainly characterized by hypertensive HF with fluid accumu-
lation (Figure 2), and with higher doses of furosemide
intravenous administration (Table 2). Although our data also
suggest that diuretics therapy enhances serum creatinine
levels, statistically strong differences in diuretics dose were
not found between below- and above-median NT-proBNP/
emBNP groups (P=0.138, furosemide intravenous administra-
tion dose for first 3 days after admission). These findings also
support the idea that this ratio can be a useful biomarker for
risk stratification for patients with WRF, with less association
with diuretics dosages.
BNP Clearance in Patients With Acute HF
In contrast to the multistep clearance of mature BNP via NPR-
A or NPR-C,30 NT-proBNP is cleared mainly through urinary
excretion. As a result, its levels are strongly associated with
renal function. The association between NT-proBNP/emBNP
ratios and eGFR can be seen in Figure 5C. Consistent with
earlier studies,31,32 NT-proBNP levels tended to be higher in
older patients, women, and those with higher CRP levels. We,
therefore, performed the multivariable analysis of these
associations summarized in Table 5.
Interestingly, NPR-C is reportedly upregulated in patients
with HF15; and NPR-A is also reportedly upregulated in
experimental models of hypertension.16 It is also reported
that this upregulated expression is transiently decreased
after ischemic reperfusion in kidney, but subsequently
recovers.17 The study suggests NPRs are upregulated within
several days after renal impairment. Another study reported
there is no difference between fractional extraction of BNP
and NT-proBNP, suggesting that there are no differences in
the clearance behavior of the 2 peptides after glomerular
filtration in patients with hypertension33; nonetheless, in this
study, it is probable that enhanced expression of receptors
mediating biological activity or clearance could potentially
contribute to elevating NT-proBNP/emBNP ratios in the first
several days after admission. Consistent with this idea, we
observed that cGMP levels, a second messenger for mature
BNP, were higher in patients with above-median NT-proBNP/
emBNP ratio than in those with below-median NT-proBNP/
emBNP ratio only on day 3 after hospital admission
(Figure 4B); however, no differences were found in use of
carperitide between the 2 groups. In addition, although it is
well known that plasma cGMP levels are influenced by nitric
oxide (NO). donor therapies, there were no significant
differences in use of these therapies, such as nitrate and
phosphodiesterase type 5 inhibitor, between the patients
with below- and above-median NT-proBNP/emBNP ratios.
These findings raise the possibility that NPR-A is upregulated
at this time, and NPR-A–mediated consumption of mature
BNP is associated with elevation of cGMP levels. Further-
more, emBNP levels were lower in the patients with WRF
Table 4. Association of emBNP and NT-proBNP Levels and
NT-proBNP/emBNP Molar Ratio on Day 3 With Percentage
Decreases in eGFR (Unadjusted)
Variable Parameter Estimate 95% CI P Value
emBNP level 0.087 0.523 to 0.350 0.696
NT-proBNP level 0.027 0.048 to 0.006 0.011
NT-proBNP/
emBNP ratio
1.437 2.162 to 0.712 <0.001
eGFR indicates estimated glomerular filtration rate; emBNP, estimated mature B-type
natriuretic peptide; NT-proBNP, N-terminal B-type or brain natriuretic peptide.
Table 5. Association of the NT-proBNP Levels on Day 3 With
Percentage Decreases in eGFR
Model Parameter Estimate 95% CI P Value
1 0.029 0.050 to 0.008 0.007
2 0.024 0.046 to 0.002 0.033
3 0.022 0.043 to 0.002 0.034
4 0.031 0.052 to 0.009 0.005
5 0.017 0.033 to 0.002 0.032
Model 1, adjusted for age and sex. Model 2, adjusted for age, sex, and eGFR (day 3).
Model 3, adjusted for age, sex, and total dosage of intravenous furosemide for first
3 days. Model 4, adjusted for age, sex, and systolic blood pressure (BP) on admission.
Model 5, adjusted for age, sex, eGFR, total dosage of intravenous furosemide
administration for first 3 days, and systolic BP on admission. eGFR indicates estimated
glomerular filtration rate; NT-proBNP, N-terminal pro-B-type or brain natriuretic peptide.
Table 6. Association of the NT-proBNP/emBNP Molar Ratio
on Day 3 With Percentage Decreases in eGFR
Model Parameter Estimate 95% CI P Value
1 1.504 2.239 to 0.769 <0.001
2 1.364 2.156 to 0.573 <0.001
3 1.226 1.974 to 0.477 0.002
4 1.504 2.242 to 0.767 <0.001
5 0.942 1.800 to 0.085 0.032
Model 1, adjusted for age and sex. Model 2, adjusted for age, sex, and eGFR (day 3).
Model 3, adjusted for age, sex, and total dosage of intravenous furosemide for first
3 days. Model 4, adjusted for age, sex, and systolic blood pressure (BP) on admission.
Model 5, adjusted for age, sex, eGFR, total dosage of intravenous furosemide
administration for first 3 days, and systolic BP on admission. eGFR indicates estimated
glomerular filtration rate; emBNP, estimated mature B-type or brain natriuretic peptide;
NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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than in those without WRF on day 3 after admission and
thereafter (Figure 3D), but there was no significant difference
in NT-proBNP levels (Figure 3B). These findings are consisted
with our hypothesis that NPRs mediate consumption of
mature BNP in patients with WRF, leading to elevation of NT-
proBNP/emBNP ratios in patients with WRF.
In addition, it is widely known that the NT-proBNP has
several times longer half-life than mature BNP (120 versus
20 minutes). As shown in Figure 5, association of eGFR with
NT-proBNP/emBNP ratio on admission was better than that of
eGFR with each BNP form (NT-proBNP and emBNP). Interest-
ingly, NT-proBNP was also well associated with eGFR
compared with emBNP. On the basis of the above hypothesis
of rapid consumption of emBNP via NPR-A, using combination
of NT-proBNP, NT-proBNP/emBNP ratio may be a reasonable
predictor for WRF in patients with ADHF because NT-proBNP
was well correlated with eGFR at each time point.
Risk Stratification in Patients With Cardiorenal
Syndrome
Our data demonstrated that the NT-proBNP/emBNP ratio on
admission was strongly associated with clinical outcomes in
patients with acute HF and WRF (Table 7). By contrast,
previous studies have suggested that BNP levels are higher in
patients with renal impairment than in those with similar LV
end-diastolic pressure and function, but without renal impair-
ment,34 and that BNP (total BNP in this study) alone is less
predictive of future adverse clinical events in patients with
advanced stages of chronic kidney disease.35 Indeed, in
patients with WRF, association of NT-proBNP levels, measured
on hospital admission, with future adverse clinical events was
weak. These findings of measurement timing of BNP are
consistent with earlier studies showing that the predictive-
ness of BNP on admission was weaker than at the time of
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Figure 5. Association between NT-proBNP (N-terminal pro-B-type or brain natriuretic peptide)/estimated mature BNP (emBNP) ratios and
estimated glomerular filtration rate (eGFR) in patients with acute decompensated heart failure. A, Association between the log emBNP levels and
log eGFR. B, Association between the log NT-proBNP levels and log eGFR. C, Association between the log NT-proBNP/emBNP ratio and log
eGFR. D, Association between the log NT-proBNP/emBNP ratio and log eGFR in patients with above-median NT-proBNP (≥525.4 pmol/L) (red
plot) or below-median NT-proBNP (<525.4 pmol/L) (blue plot). The interaction term between NT-proBNP and NT-proBNP/emBNP ratio was
significant (P=0.010).
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NT-proBNP/emBNP ratios and eGFR was found in patients
with above-median NT-proBNP levels (indicating more severe
acute HF) than in patients with below-median NT-proBNP
levels (indicating milder acute HF) (Figure 5D). This suggests
HF severity, which was indicated by NT-proBNP levels, is also
associated with a steeper correlation between eGFR and NT-
proBNP/emBNP ratios. These findings suggest that this ratio
might be influenced by pathophysiological characteristics in
both the heart and kidney.
Taken together, the present study raises a possibility that
the NT-proBNP/emBNP ratio is a novel predictor candidate of
clinical outcome and is useful for risk stratification of patients
with acute HF complicated by WRF. Circulating BNP levels are
mainly regulated by cardiac production and provide informa-
tion about cardiac status, whereas combined assessments of
NT-proBNP and emBNP add useful information about renal
status and can predict occurrences of WRF.
Limitations
The present study has several limitations. First, this was a
single-center investigation with a limited number of patients.
However, we were able to confirm changes in the ratio of BNP
molecular forms during the short-term phase of HF. Second,
there was no significant association between the NT-proBNP/
emBNP ratio or eGFR on hospitalization day 3 and
occurrences of WRF (receiver operating characteristic curves
and C-statistics). Given the number of enrolled patients, this
suggests the study lacked sufficient power to determine
whether those parameters are predictive of WRF occurrence
in the patients with acute HF. We, therefore, think that larger-
scale investigations are needed to confirm our findings.
Nonetheless, we demonstrated that there are changes in the
natriuretic peptide profile during hospitalization and that
changes in the NT-proBNP/emBNP ratio precede the changes
in renal function. These findings may provide important
evidence that could help in the design of future clinical
studies.
Third, some of the patients did not receive a blood test
after day 3 (n=18; 10% of the overall patient group), after day
7 (n=23; 13% of the overall patient group), or before discharge
(n=38; 21% of the overall patient group). We excluded patients
for whom we did not have all 3 blood samples (n=38; 21% of
overall patients) from the analysis of the time-dependent
changes in the natriuretic peptide profile. Consequently, that
analysis was performed with 79% of the enrolled patients.
Because this study aimed to elucidate the association
between natriuretic peptide levels at admission and future
clinical outcomes during hospitalization, for all other analyses,
we did not exclude the data from those patients.
Fourth, it is difficult to elucidate the relation between the
interaction of the respective BNP molecular forms with NPRs
and levels of circulating mature BNP in clinical settings. Fifth,
we did not measure levels of other biomarkers, such as
tubulospecific markers, that had not been planned in this
study. Future investigations will be necessary to determine
their relation to the NT-proBNP/emBNP ratio and to clarify the
relation between this ratio and tubular function in the patients
with and without WRF.
Conclusion
We demonstrated the differences in changes in NT-proBNP
and emBNP between patients with acute HF with and without
WRF. NT-proBNP/emBNP molar ratios are strongly associated
with renal function during the short-term phase of acute HF
and with adverse clinical events. This ratio provides informa-
tion about patients with cardiorenal syndrome that cannot be
derived from measurements of total BNP or eGFR individually
and also provides valuable information about pathophysiolog-
ical characteristics in both the heart and kidney.
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Table 7. Predictive Values for Composite Clinical Events in
Patients With ADHF




Log NT-proBNP 1.44 1.09–1.94 0.011
Log NT-proBNP/emBNP ratio 1.05 0.67–1.67 0.815
WRF (+)
Log NT-proBNP 1.05 0.67–1.67 0.815




Log NT-proBNP 1.65 1.27–2.16 <0.001
Log NT-proBNP/emBNP ratio 1.28 0.86–1.83 0.217
WRF (+)
Log NT-proBNP 1.42 0.92–2.15 0.110
Log NT-proBNP/emBNP ratio 1.78 0.98–3.34 0.060
ADHF indicates acute decompensated heart failure; emBNP indicates estimated mature
B-type or brain natriuretic peptide; HR, hazard ratio; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; WRF, worsening renal function.
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